Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK
Bristol-Myers’ $BMY Opdivo may be about to cede its top place in the PD-1/L1 world to Merck, but in China today, they’re number 1. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
